COVID-19 from Pfizer and BioNTech appears to be effective against 16 different coronavirus mutations, according to a study that has not yet been peer-reviewed.
As reported by Reuters, the study by researchers at Pfizer and the medical branch of the University of Texas suggests that the vaccine will not need to be modified to work against a seemingly more contagious variant of the coronavirus that has appeared in the UK.
The British variant, known as B117, was recently detected in the United States among people who had not traveled to the UK, indicating the spread of the community.
Viral mutations are a typical occurrence and there is no indication that anyone has so far made COVID-19 more dangerous than it already is. And, although vaccines can be modified to address new variations, there is still no sign that is needed.
“So we’ve tested 16 different mutations now, and none of them have really had a significant impact. That’s good news,” Phil Dormitzer, a scientist at Pfizer, said Thursday. – That doesn’t mean the 17th doesn’t.
This article was originally published by Business Insider.
More from Business Insider: